[go: up one dir, main page]

DK2919796T3 - Brug af akkermansia til behandling af stofskiftesygdomme - Google Patents

Brug af akkermansia til behandling af stofskiftesygdomme Download PDF

Info

Publication number
DK2919796T3
DK2919796T3 DK13792006.2T DK13792006T DK2919796T3 DK 2919796 T3 DK2919796 T3 DK 2919796T3 DK 13792006 T DK13792006 T DK 13792006T DK 2919796 T3 DK2919796 T3 DK 2919796T3
Authority
DK
Denmark
Prior art keywords
metable
akkermansia
diseases
treatment
metable diseases
Prior art date
Application number
DK13792006.2T
Other languages
English (en)
Inventor
Clara Belzer
Vos Willem De
Patrice Cani
Amandine Everard
Original Assignee
Univ Catholique Louvain
Univ Wageningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47257788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2919796(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Catholique Louvain, Univ Wageningen filed Critical Univ Catholique Louvain
Application granted granted Critical
Publication of DK2919796T3 publication Critical patent/DK2919796T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
DK13792006.2T 2012-11-19 2013-11-15 Brug af akkermansia til behandling af stofskiftesygdomme DK2919796T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/073011 WO2014075745A1 (en) 2012-11-19 2012-11-19 Use of akkermansia for treating metabolic disorders
PCT/EP2013/073972 WO2014076246A1 (en) 2012-11-19 2013-11-15 Use of akkermansia for treating metabolic disorders

Publications (1)

Publication Number Publication Date
DK2919796T3 true DK2919796T3 (da) 2021-05-31

Family

ID=47257788

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13792006.2T DK2919796T3 (da) 2012-11-19 2013-11-15 Brug af akkermansia til behandling af stofskiftesygdomme

Country Status (14)

Country Link
US (8) US20150306152A1 (da)
JP (2) JP6426616B2 (da)
KR (5) KR102581171B1 (da)
CN (2) CN104918626B (da)
AU (1) AU2013346726B2 (da)
BR (1) BR112015011403A2 (da)
CA (1) CA2891758C (da)
DK (1) DK2919796T3 (da)
EA (2) EA202100040A3 (da)
ES (1) ES2871817T3 (da)
HK (1) HK1215375A1 (da)
MX (1) MX365835B (da)
PT (1) PT2919796T (da)
WO (2) WO2014075745A1 (da)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN105407728A (zh) 2013-07-21 2016-03-16 霍勒拜欧姆公司 用于微生物组表征、监测和治疗的方法和系统
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
KR101740893B1 (ko) 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
JP6868562B2 (ja) 2014-10-31 2021-05-19 ペンデュラム セラピューティクス， インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
KR20220151045A (ko) 2014-12-23 2022-11-11 4디 파마 리서치 리미티드 면역 조정
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
EP3783010A1 (en) 2015-05-06 2021-02-24 Wageningen Universiteit Method of culturing akkermansia
MX2017014111A (es) 2015-05-06 2018-02-26 Univ Wageningen Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico.
MX2017016529A (es) 2015-06-15 2018-03-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas.
EP3240554B1 (en) 2015-06-15 2019-07-31 4D Pharma Research Limited Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ES2910946T3 (es) 2015-06-15 2022-05-17 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
CN105030841A (zh) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
CN105106245A (zh) * 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
KR20240137695A (ko) * 2015-09-10 2024-09-20 위니베르시트카솔리끄드루뱅 암을 예방하기 위한 저온살균된 아커만시아의 용도
JP2018534277A (ja) * 2015-10-05 2018-11-22 シュヴァイツェリッシェ フォルシュングスインスティテュート フュア ホーフゲブリクスクリーマ ウント メディツィン イン ダヴォス 炎症性状態を治療するためのアッカーマンシア・ムシニフィラ（Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ）の使用
WO2017060491A1 (en) * 2015-10-09 2017-04-13 Biogaia Ab Mucus thickness to prevent diseases
CN105176822B (zh) * 2015-10-23 2019-01-11 广州康泽医疗科技有限公司 一种人类肠道益生菌的优化分离方法
ME03003B (me) 2015-11-20 2018-10-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PT3639834T (pt) 2016-02-04 2023-10-12 Univ Gent Utilização de comunidades microbianas para a saúde humana e animal
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3423093A4 (en) 2016-03-04 2019-11-13 The Regents of The University of California MICROBIAL CONSORTIUM AND USES THEREOF
TW201733601A (zh) 2016-03-04 2017-10-01 ４Ｄ製藥有限公司 包含細菌菌株之組合物
CN109415683B (zh) 2016-04-11 2022-04-15 瓦赫宁恩大学 新细菌物种
WO2018012834A1 (ko) 2016-07-11 2018-01-18 한국생명공학연구원 퇴행성 뇌질환 또는 대사성 질환의 예방 또는 치료 효과를 가지는 아커만시아 뮤시니필라 균주 및 이의 용도
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
EP3498819A4 (en) * 2016-08-12 2020-04-08 BGI Shenzhen FAECALIBACTERIUM BUTYRICIGENERANS AND CORRESPONDING CULTURE METHOD AND APPLICATION THEREOF
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11129858B2 (en) 2016-12-20 2021-09-28 The Regents Of The University Of California Compositions and methods for inhibiting seizures
CA3058943C (en) 2017-04-03 2023-10-17 Gusto Global, Llc Rational design of microbial-based biotherapeutics
FR3065643B1 (fr) 2017-04-26 2020-04-17 Usines Chimiques D'ivry La Bataille (Ucib) Composition nutraceutique et/ou pharmaceutique pour stimuler la production de beta-defensines de type 2
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
JP2020520911A (ja) 2017-05-22 2020-07-16 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
HUE052319T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
IL283973B (en) 2017-06-14 2022-08-01 4D Pharma Res Ltd Compositions comprising bacterial strains
TWI640314B (zh) * 2017-08-22 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途
TWI636788B (zh) * 2017-08-28 2018-10-01 長庚生物科技股份有限公司 戈氏副擬桿菌用於抑制脂肪肝疾病之用途
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
WO2019092896A1 (ja) * 2017-11-08 2019-05-16 アサヒグループホールディングス株式会社 アッカーマンシア・ムシニフィラ増殖材
JP2021504420A (ja) * 2017-11-30 2021-02-15 グリコム・アクティーゼルスカブＧｌｙｃｏｍ Ａ／Ｓ 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物
KR20200128126A (ko) * 2018-03-02 2020-11-11 아카데미쉬 메디쉬 센트럼 자가 면역 질환의 예방 또는 치료를 위한 대변
WO2019199895A1 (en) 2018-04-10 2019-10-17 Siolta Therapeutics, Inc. Microbial consortia
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
KR102225939B1 (ko) * 2018-04-19 2021-03-10 주식회사 고바이오랩 신규한 Bacteroides vulgatus 균주 및 이를 유효 성분으로 하는 면역 및 대사성 질환 예방 또는 치료용 조성물
WO2019222359A1 (en) * 2018-05-15 2019-11-21 Duke University Systems and methods for genetic manipulation of akkermansia species
CN110496140B (zh) * 2018-05-18 2022-05-31 瑞微（深圳）生物科技有限公司 脆弱拟杆菌或阿克曼粘细菌在制备用于预防或治疗肿瘤的药物中的应用
US20210364526A1 (en) * 2018-05-23 2021-11-25 The Regents Of The University Of California Methods of selecting subjects for treatment with metabolomic modulators
EP3594321A1 (en) * 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
CN112584847A (zh) * 2018-08-20 2021-03-30 默多克儿童研究所 行为治疗
CN110964650B (zh) * 2018-09-27 2022-10-11 上海上药信谊药厂有限公司 一种用于预防和治疗代谢疾病的菌株及其应用
KR102377407B1 (ko) * 2018-10-01 2022-03-22 한국생명공학연구원 아커만시아 뮤시니필라 균주 또는 이의 배양물을 유효성분으로 함유하는 노화방지용 조성물
KR102197180B1 (ko) * 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
WO2020076136A2 (ko) * 2018-10-11 2020-04-16 서울대학교산학협력단 아커만시아 뮤시니필라 균주 및 이의 용도
ES2970821T3 (es) * 2018-12-21 2024-05-30 Salomon Amar Uso de Akkermansia en el tratamiento de enfermedades orales
WO2020221899A1 (en) * 2019-05-02 2020-11-05 Université Catholique de Louvain Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer
JP7402629B2 (ja) * 2019-07-19 2023-12-21 国立大学法人東京農工大学 プロピオン酸菌発酵物含有組成物
TWI719549B (zh) * 2019-07-22 2021-02-21 大江生醫股份有限公司 促進嗜黏蛋白艾克曼菌生長之益生質組合物
KR102128287B1 (ko) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 아커만시아 뮤시니필라 eb-amdk19 균주 및 그의 용도
KR102128289B1 (ko) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 아커만시아 뮤시니필라 eb-amdk27 균주 및 그의 용도
CN115087727B (zh) * 2019-09-25 2025-03-18 健康生物公司 用于癌症治疗的专性厌氧人肠道微生物及其用途
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
JP7624449B2 (ja) 2019-10-07 2025-01-30 シオルタ・セラピューティクス，インコーポレイテッド 治療用医薬組成物
CN110698547B (zh) * 2019-10-31 2023-01-03 南京农业大学 重组表达的阿克曼菌膜蛋白Amuc_1100及其应用
CN110786376A (zh) * 2019-11-07 2020-02-14 中南大学湘雅医院 嗜黏蛋白艾克曼氏灭活菌在制备酸奶中的应用及酸奶的制备方法和应用
CN111202752A (zh) * 2020-02-17 2020-05-29 上海市内分泌代谢病研究所 阿克曼氏菌组合物
CN111228315A (zh) 2020-02-27 2020-06-05 上海上药信谊药厂有限公司 抗肿瘤组合物
CN111450233B (zh) * 2020-03-19 2021-04-13 中国农业大学 一种微生物代谢产物在缓解糖脂代谢紊乱中的应用
KR102671044B1 (ko) * 2020-03-25 2024-05-31 한국생명공학연구원 아커만시아 뮤시니필라 유래의 tars 또는 이의 단편 및 이의 용도
CA3174352A1 (en) * 2020-04-03 2021-10-07 Sofia FORSSTEN Compositions for metabolic health
WO2021215828A1 (ko) * 2020-04-24 2021-10-28 주식회사 고바이오랩 Glp-1 유도 활성을 갖는 단백질 변이체 및 이의 용도
CN111996267A (zh) * 2020-08-11 2020-11-27 康美华大基因技术有限公司 一种快速检测akk菌的荧光定量pcr引物组、试剂盒及其应用
KR102185827B1 (ko) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 아커만시아 뮤시니필라 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물
BE1028339B1 (fr) * 2020-11-09 2021-12-21 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
CN113116936A (zh) * 2021-04-02 2021-07-16 上海市第六人民医院 嗜黏蛋白艾克曼氏菌在制备β-鹅脱氧胆酸抑制剂中的应用
CN113322202B (zh) * 2021-05-31 2022-03-01 君维安(武汉)生命科技有限公司 一种阿克曼氏菌、其培养方法及其应用
JP7398714B2 (ja) * 2021-06-28 2023-12-15 東栄新薬株式会社 医療・美容に応用可能なアッカーマンシア・ムシニフィラ増殖促進用組成物およびこれを含む医薬、飲食品、飼料
CN113862193B (zh) * 2021-10-28 2023-12-22 江西普瑞森基因科技有限公司 一株嗜黏蛋白阿克曼氏菌及其在制备抗肿瘤药物中的应用
EP4429703A1 (en) * 2021-11-12 2024-09-18 Gelesis, LLC. Compositions and methods for modulating the intestinal microbiome
CN119183472A (zh) * 2022-03-15 2024-12-24 潘德勒姆治疗公司 新型微生物组合物和其使用方法
CN118638600A (zh) * 2022-03-24 2024-09-13 浙江省农业科学院 具有降血脂作用的益生菌组合物的制备设备
CN114949003B (zh) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌及其应用和培养方法
CN115252651B (zh) * 2022-06-08 2024-06-07 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备防治高血压的组合物中的应用和含有其的组合物
CN116115647B (zh) * 2022-06-08 2024-12-20 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备改善代谢综合征的药物组合物或保健品组合物中的应用
CN115804793A (zh) * 2022-06-08 2023-03-17 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备改善酒精性肝功能异常的组合物中的应用、组合物及应用
CN114949002B (zh) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备防治动脉粥样硬化的组合物中的应用
CN115463159A (zh) * 2022-09-26 2022-12-13 暨南大学附属第一医院（广州华侨医院） 一种阿克曼菌及阿克曼菌后生元在制备预防或治疗肝脏脂肪病变的药物或保健品中的应用
CN115747357A (zh) * 2022-11-15 2023-03-07 迪辅乐生物(上海)有限公司 肠道嗜粘蛋白-阿克曼氏菌的检测试剂盒及其检测方法
WO2024134035A1 (fr) * 2022-12-22 2024-06-27 Sorbonne Universite Composition et utilisation de turicimonas muris pour le traitement de maladies métaboliques
CN116077536B (zh) * 2023-03-17 2023-11-28 微康益生菌(苏州)股份有限公司 一种用于改善肥胖相关代谢疾病的微生态活菌制剂及其制备方法和应用
CN116999468B (zh) * 2023-08-18 2024-11-15 善恩康生物科技（苏州）有限公司 Akkermansia muciniphila在制备预防、治疗和/或辅助治疗心血管疾病的产品中的应用
CN117603884B (zh) * 2024-01-17 2024-03-26 广州同康生物科技有限公司 一种嗜黏蛋白阿克曼氏菌菌粉及其制备方法
CN118178476A (zh) * 2024-04-03 2024-06-14 暨南大学附属第一医院（广州华侨医院） 阿克曼菌及其制剂在制备促进排便、排脂、减少肠道脂肪吸收的药物中的应用
CN118207140B (zh) * 2024-05-20 2024-09-17 微康益生菌(苏州)股份有限公司 一种具有调节血糖血脂功效的嗜粘蛋白阿克曼氏菌Akk11及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100172874A1 (en) 2006-12-18 2010-07-08 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) * 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
EP2542690A2 (en) 2010-03-01 2013-01-09 Institut National de la Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
US9173910B2 (en) * 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders

Also Published As

Publication number Publication date
KR20210111871A (ko) 2021-09-13
BR112015011403A2 (pt) 2018-02-06
CA2891758A1 (en) 2014-05-22
CN104918626B (zh) 2020-07-07
KR20230080492A (ko) 2023-06-07
AU2013346726B2 (en) 2017-11-02
MX365835B (es) 2019-06-17
US20190282630A1 (en) 2019-09-19
EA201500535A1 (ru) 2016-03-31
US20200121737A1 (en) 2020-04-23
HK1215375A1 (zh) 2016-08-26
PT2919796T (pt) 2021-06-02
EA037315B1 (ru) 2021-03-11
US20210322489A1 (en) 2021-10-21
KR102581171B1 (ko) 2023-09-21
JP2019048825A (ja) 2019-03-28
US20200155616A1 (en) 2020-05-21
KR20150093711A (ko) 2015-08-18
KR20240137696A (ko) 2024-09-20
JP6426616B2 (ja) 2018-11-21
KR102297388B1 (ko) 2021-09-03
US20210393704A1 (en) 2021-12-23
CN104918626A (zh) 2015-09-16
AU2013346726A1 (en) 2015-06-04
JP2016503418A (ja) 2016-02-04
ES2871817T3 (es) 2021-11-02
EA202100040A2 (ru) 2021-06-30
CN111603488B (zh) 2024-04-05
CN111603488A (zh) 2020-09-01
EA202100040A3 (ru) 2021-10-29
CA2891758C (en) 2022-06-07
WO2014075745A1 (en) 2014-05-22
US20150306152A1 (en) 2015-10-29
US20200237832A1 (en) 2020-07-30
WO2014076246A1 (en) 2014-05-22
KR20230121938A (ko) 2023-08-21
MX2015006234A (es) 2015-10-29
US20200237833A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
LT2885010T (lt) Tautopatijos gydymo būdai
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
HK1195311A1 (zh) 用於治療變性疾病和炎性疾病的新化合物
HK1211210A1 (zh) 治療多發性硬化症的組合療法
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
HUE041891T2 (hu) Berendezés ipari célokra használt víz kezelésére
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
EP2906208A4 (en) THERAPEUTIC TREATMENT
LT3292875T (lt) Kompozicijos ir būdai, skirti ligų gydymui
DK3040336T3 (da) Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
IL231092A0 (en) Treatment of rhinitis
FR2994831B1 (fr) Prothese de main.
EP2907431A4 (en) SHOWER HEAD
DK2838907T3 (da) Aminosteroider til behandlingen af en ptp1b-associeret sygdom
EP2718255A4 (en) QUINONE COMPOUNDS FOR THE TREATMENT OF APE1 MEDIATION DISEASES
BR112014026553A2 (pt) Fralda descartável
LT2812013T (lt) Kompozicija, skirta džs gydymui
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
DK2900259T3 (da) Glycosidase-regime til behandling af infektionssygdomme
DK2892556T3 (da) Sammensætninger og fremgangsmåder til behandling af sygdomme
DK2705847T3 (da) Sammensætning til behandling af psoriasis
DK2928454T3 (da) Triaziner til behandling af protozosygdomme